Mycophenolate Mofetil Hexal

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Hexal, is an antimetabolite immunosuppressant presented as an oral dosage form for oral use. It is used to prevent acute organ‑transplant rejection and to treat lupus nephritis. GNH USA supplies Mycophenolate Mofetil Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is employed in the management of immune‑mediated conditions, particularly those requiring suppression of lymphocyte activity.

Kidney transplantation: prevents acute rejection and supports graft survival. Heart transplantation: reduces the risk of early rejection episodes. Liver transplantation: helps maintain graft function by inhibiting immune response. Lupus nephritis: treats renal involvement by dampening autoimmune inflammation.

Adverse reactions may occur with Mycophenolate Mofetil therapy.

Common Side Effects: - Nausea or vomiting. - Diarrhea or abdominal discomfort. - Headache. - Tremor or mild dizziness. - Increased susceptibility to mild infections.

Serious or Rare Side Effects: - Severe infections, including opportunistic pathogens. - Bone‑marrow suppression leading to leukopenia or anemia. - Hepatotoxicity with elevated liver enzymes. - Increased risk of malignancies, especially lymphoproliferative disorders. - Progressive multifocal leukoencephalopathy (PML).

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor relevant parameters. - Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess renal function: adjust dose in patients with impaired clearance. - Avoid in pregnancy: contraindicated (Category X) due to teratogenic risk. - Use effective contraception: required for women of child‑bearing potential. - Store at room temperature: keep in the original pack, protect from moisture.

Mycophenolate Mofetil can interact with several agents, altering its exposure or safety profile.

Major Interactions (Avoid): - Cyclosporine: increases mycophenolate exposure, raising toxicity risk. - Tacrolimus: may elevate mycophenolate levels, requiring close monitoring. - Live vaccines: heightened infection risk; avoid concurrent use.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce oral absorption. - Azathioprine: additive bone‑marrow suppression potential. - Rifampin or other enzyme inducers: can lower mycophenolate concentrations.